Heterologous Omicron-adapted vaccine as a secondary booster promotes neutralizing antibodies against Omicron and its sub-lineages in mice
| Autor: | Jianyang Liu, Qian He, Fan Gao, Lianlian Bian, Qian Wang, Chaoqiang An, Lifang Song, Jialu Zhang, Dong Liu, Ziyang Song, Lu Li, Yu Bai, Zhongfang Wang, Zhenglun Liang, Qunying Mao, Miao Xu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Emerging Microbes and Infections, Vol 12, Iss 1 (2023) |
| Druh dokumentu: | article |
| ISSN: | 22221751 2222-1751 |
| DOI: | 10.1080/22221751.2022.2143283 |
| Popis: | ABSTRACTOver one billion people have received 2–3 dosages of an inactivated COVID-19 vaccine for basic immunization. Whether a booster dose should be delivered to protect against the Omicron variant and its sub-lineages, remains controversial. Here, we tested different vaccine platforms targeting the ancestral or Omicron strain as a secondary booster of the ancestral inactivated vaccine in mice. We found that the Omicron-adapted inactivated viral vaccine promoted a neutralizing antibody response against Omicron in mice. Furthermore, heterologous immunization with COVID-19 vaccines based on different platforms remarkably elevated the levels of cross- neutralizing antibody against Omicron and its sub-lineages. Omicron-adapted vaccines based on heterologous platforms should be prioritized in future vaccination strategies to control COVID-19. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|